-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1518 Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group

Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I
Hematology Disease Topics & Pathways:
Research, Combination therapy, Clinical Research, Real-world evidence, Treatment Considerations
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Emmanuelle Tavernier, MD1*, Jérôme Cornillon1*, Zofia Gross, MD2*, Gaspar Aspas Requena3*, Urbain Tauveron-Jalenques3*, Martin Carré, MD4*, Mathieu Meunier5*, Ugo Thévenet, MD1*, Boullanger Fow Heng Nadine6*, Clémence Santana7*, Clément Rocher, MD8*, Sylvain Lamure, MD, PhD9*, Amine Belhabri, MD10*, Mauricette Michallet, MD, PhD10, Adrien Contejean11*, Natacha Mauz11*, Gian Matteo Pica, MD12*, Arthur Dony12* and Mael Heiblig2*

1Département d'hématologie Clinique et de Thérapie Cellulaire, CHU Saint-Etienne, Saint-Etienne, France
2Département d'Hématologie, CHU de Lyon, Pierre-Bénite, France
3Département d'Hématologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France
4Département d'Hématologie, CHU de Grenoble Alpes, Grenoble, France
5Department of Hematology CHU Grenoble Alpes, Grenoble, France
6Département d'Onco-Hématologie, CH de Roanne, Roanne, France
7Département d'Hématologie, CH de Valence, Valence, France
8Département d'Hématologie, Centre Hospitalier Bourgoin Jallieu, Bourgoin Jallieu, France
9Département d'Onco-Hématologie, Hôpitaux Nord-Ouest, Villefranche-sur-Saone, France
10Département de Cancérologie médicale, Centre Léon Bérard, Lyon, France
11Département d'Hématologie, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France
12Département d'Hématologie, CH Chambery, Chambéry, France

Even if therapeutic arsenal has improved the prognosis of acute myeloid leukemia (AML), relapse remains a challenge especially in post allogenenic stem cell transplantation (ASCT) settings. Therapeutic options in this situation are usually limited and prognostic remains poor. While azacitidine and venetoclax (AZA/VEN) combination regimen is now a standard of care in frontline settings for unfit AML patients, it is nowadays used as an off-label therapeutic approach in relapse/refractory settings after ASCT. In this multicentric study, we aimed to evaluate the efficacy and safety of AZA/VEN regimen for relapse/refractory (R/R) AML patients after ASCT in real life setting.

Patients from the VENAURA registry (N=585) with following criteria were included in this study: patients transplanted for AML or other high-risk myeloid neoplasm (MDS/AML, CMML-2) who cytologically relapse after ASCT. Data were retrospectively collected in the VENAURA registry from 12 different French centers (Saint-Etienne, Clermont-Ferrand, Lyon (Hopital Lyon Sud, Centre Léon Bérard), Vichy, Annecy, Chambery, Valence, Bourgoin-Jallieu, Grenoble, Roanne) in Auvergne Rhône Alpes (AURA) region, between January 2019 and February 2024. Composite complete remission CRc was defined as in VIALE-A trial. Measurable residual disease (MRD) negativity was defined as 10-3 by flow cytometry (in the bone marrow), 10-3 for WT1 by RT-qPCR and/or 10-4 for NPM1 by RT-qPCR.

Overall, 52 patients (AML=49, myeloid sarcoma=1, MDS/AML=1, CMML-2=1) received AZA/VEN combination regimen for relapse after ASCT. Median time between ASCT and relapse was 12.8 months (1-182). Eleven patients received azacitidine as monotherapy prior venetoclax introduction for mixed chimerism/molecular relapse (n=7) or cytologic relapse (n=4). Patients received a median number of 3 AZA/VEN cycles (1-23). Median time between relapse and AZA/VEN onset was 1.5 months (0.2-24) with a median duration of cycle 1 of 21 days (7-28). During C1, febrile neutropenia and tumor lysis syndrome was observed in 40.7% and 7.8% of cases respectively. During follow-up, 27 patients presented with acute GVHD including 12 grade 1, 11 grade 2 and 4 grade 3. No grade 4 GVHD occurred. Fourteen patients developed chronic GVH, 5 of them in extensive form. For patients evaluated at the end of cycle 1 (N=38), overall response rate (CRc) was 47.3% (18/38) with 12 CR and 6 CRi respectively. In responding patients evaluable for MRD at the end of cycle 1 (N=13), 30.7% were MRD negative. For non-responding patients at the end of C1 (N=21), 13 received subsequent cycles of which 4/13 (30.7%) reached CR/CRi/MLFS. Overall, 18.3%, 26.5% and 12.2% of evaluable patients reached CRMRD-, CRMRD+, and CR with unknown MRD status. Median duration of CRc was 12.2 and 3.9 months in CRMRD- and CRMRD+ patients respectively (p=0.02). With a median follow-up of 8.7 months since AZA/VEN onset, median overall survival (OS) was 17.1 months. Patients with CRMRD- have a significant superior outcome compared to those in CRMRD+ (p=0.023). During follow-up, 40.4% of patients received donor lymphocyte infusions (DLIs) either prior AZA/VEN onset (N=9) or after (N=8) which did not seem to influence ASCT outcome. Five patients received a second ASCT in CRc following AZA/VEN salvage of which 2 ultimately relapsed after the second transplantation.

To our knowledge, this is one of the largest cohort reporting AZA/VEN combination regimen efficacy and safety in post-ASCT AML relapse settings. In this real-life settings study, those results suggest that AZA/VEN combination regimen yielded promising results with a reasonable toxicity profile in post-ASCT AML relapse settings. Reaching CRMRD- was associated with a better outcome and it might represent a good option to optimize graft versus leukemia through immunomodulatory approaches before considering DLI or a second allogeneic transplantation.

Disclosures: Tavernier: Pfizer: Other; BMS: Honoraria. Aspas Requena: Novartis: Honoraria; Pfizer: Honoraria; Abbvie: Honoraria; BMS: Honoraria; Janssen: Honoraria. Meunier: Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy; Alexion: Consultancy; BMS: Membership on an entity's Board of Directors or advisory committees; GSK: Speakers Bureau. Santana: Sanofi: Honoraria; BMS/Celgene: Honoraria; Abbvie: Honoraria. Rocher: ASTRAZENECA: Consultancy; BRISTOL MYERS SQUIBB: Research Funding; Pierre OUDOT hospital: Current Employment. Lamure: Janssen: Other, Research Funding; Gilead: Other; Roche Pharma: Other; Abbvie: Other; Sanofi: Other; Novartis: Other; Actelion: Other; Pfizer: Other. Contejean: Janssen: Honoraria; BMS: Honoraria; Abbvie: Honoraria; Pfizer: Honoraria; Novartis: Honoraria. Dony: Stemline: Honoraria; Sanofi: Honoraria, Other; BMS: Honoraria; Abbvie: Honoraria. Heiblig: Pfizer: Honoraria; Abbvie: Honoraria; Jazz pharmaceutical: Honoraria; Servier: Honoraria; Astellas: Honoraria.

*signifies non-member of ASH